<DOC>
	<DOCNO>NCT00319995</DOCNO>
	<brief_summary>This Phase 3 , randomize , parallel-group , multicenter , double-dummy , double-blind study screen period . Subjects receive one follow three treatment group 15 day : loratadine 10 mg/montelukast 10 mg combination , pseudoephedrine 240 mg , placebo . The primary objective study assess efficacy combination loratadine/montelukast , once-daily tablet contain 10 mg loratadine 10 mg montelukast , compare placebo subject seasonal allergic rhinitis ( SAR ) relieve symptom nasal congestion . The safety profile combine loratadine/montelukast relative placebo pseudoephedrine also evaluate .</brief_summary>
	<brief_title>Effects Loratadine/Montelukast v Pseudoephedrine Placebo Patients With Seasonal Allergic Rhinitis ( Study P04095 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Aged 15 year old , either sex race . At least 2year documented history SAR symptom study season . A positive skinprick test response seasonal Clinically symptomatic Screening Baseline Visits General good health . Freedom clinically significant disease , SAR , would interfere study evaluation . Willingness ( subject and/or parent/guardian ) give write informed consent ability adhere dose visit schedule meet study requirement . Negative pregnancy test A history anaphylaxis and/or severe local reaction ( ) skin test . Asthma require chronic use inhale systemic corticosteroid . Current history frequent , clinically significant sinusitis chronic purulent postnasal drip . Rhinitis medicamentosa . A history allergies two class medication allergy intolerance antihistamine , montelukast , pseudoephedrine . An upper respiratory tract sinus infection require antibiotic therapy without least 14 day washout prior Screening Visit , viral upper respiratory infection within 7 day Screening Visit . Nasal structural abnormality , include large nasal polyp mark septal deviation , significantly interfere nasal air flow . Dependence ( opinion investigator ) nasal , oral , ocular decongestant , nasal topical antihistamine , nasal steroid . Narrowangle glaucoma , increase intraocular pressure , urinary retention , hypertension , severe coronary artery disease , ischemic heart disease , diabetes mellitus , hyperthyroidism , renal impairment , prostatic hypertrophy , receive monamine oxidase ( MAO ) inhibitor therapy . Use drug investigational protocol 30 day Screening Visit . Current immunotherapy ( desensitization therapy ) , unless regular maintenance schedule prior Screening Visit , maintain remainder study . No desensitization treatment within 24 hour visit . Requirement chronic use tricyclic antidepressant . Pregnancy lactation . Family member investigation study staff . Current evidence clinically significant hematopoietic , cardiovascular , hepatic , renal , neurologic , psychiatric , autoimmune disease , disease precludes subject 's participation study . Particular attention give exclude subject condition would currently interfere absorption , distribution , metabolism , excretion study drug interfere subject 's ability complete reliably complete diary card . Significant medical condition ( ) , judgment investigator , might interfere study require treatment . Compromised ability provide inform consent.. A history noncompliance medication treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>